Document is current
Any future updates will be listed below
-
Authors
Ferreira, Anaisa V. https://orcid.org/0000-0002-6274-0448
Domínguez-Andrés, Jorge https://orcid.org/0000-0002-9091-1961
Merlo Pich, Laura M. https://orcid.org/0009-0007-9256-8662
Joosten, Leo A. B. https://orcid.org/0000-0001-6166-9830
Netea, Mihai G. https://orcid.org/0000-0003-2421-6052
-
Funding
Funding for this research was provided by:
European Research Council (Advanced Grant (#833247))
The Netherlands Organization for Scientific Research (Spinoza Grant)
The Netherlands Organization for Scientific Research (VENI grant 09150161910024)
The Netherlands Organization for Scientific Research (Off Road 04510012010022)
- License Information
-
More Information
Article History
Received: 16 January 2024
Accepted: 2 June 2024
First Online: 25 July 2024
Declarations
: MGN is a scientific founder of Lemba Therapeutics, TTxD and Biotrip. LABJ is scientific founder of TTxD, Lemba Therapeutics and Salvina Therapeutics. The other authors have no relevant financial or non-financial interests to disclose.
